Treatment Results

Sonablate: Oncological outcomes according to different generations of devices

Courtesy of V.Mouraviev MD, PhD

Sonablate: Intermediate- and long-term oncological outcomes according to risk disease and device of different generations 

Sonablate: Intermediate- and Long-term oncological outcomes according to risk disease and device of different generations

What is HIFU?

For a Free Consultation or Second Opinion, please fill out the form below!

This information will only be used to provide you with information about HIFU. Your information will not be shared.

Total: 753 pts with up to 12 years follow-up

BDFS criteria: Phoenix

Best outcome in low- and moderate risk categories

Courtesy of V.Mouraviev MD, PhD 

Ablatherm HIFU  
(Green is treated, Red is being treated) 
Ablatherm: Long-Term Oncological outcomes 

Results of Primary HIFU Treatment using Ablatherm

MFS=Metastasis Free Survival
CSS=Cancer Specific Survival

Ganzer et al., BJUI, 2013

Results of HIFU Treatment for
Localized Prostate Cancer with 15 year followup

Patients with T1 T2 N0 M0 PSA less than 50 were treated. No patient had Androgen therapy for T3 disease. All patients were treated with Ablatherm HIFu machine. Phoenix definition was used for biochemical failure. 704 patients studied, 78.5% had intermediate or high risk disease. Mean follow up was 5.3 years (range 1.3 to 14). Cancer specific survival was 99%, metastatic free survival was 95%.

10 year treatment free rates were 98% in low, 72% in intermediate and 68% in high risk. 15% of patients had second treatment with HIFU.

Ablatherm: 10-year oncological result

References:

Ganzer R, BJU Int.2013 Aug; 112 (3): 322-9; Thuroff S, Chaussy C: J Urol.2013

Aug; 190 (2): 702-10; Crouzet S Eur Urol.2014 May; 65 (5): 907-14

Outcomes of Radical Surgery
Comparison of Surgery and HIFU

Radical Prostatectomy Outcomes at 10 years Compared to HIFU 

Outcomes of Radiation

Radiation Therapy Outcomes at 5 and 10 Years

Radiation Therapy Outcomes at 5 and 10 Years

Radiation Therapy Outcomes at 5 and 10 Years

Comparison of HIFU and Radiation 

Outcomes of Primary HIFU Treatment using Ablatherm Compared to Radiation

Reference: Ganzer et al, BJUI, 2013, Crouzet et al, AUA, 2013, Thuroff & Chaussey, JU, 2013, Zelefsky 2011, Zietman 2010, Jones 2011

Side effects/Complications of various Treatments of Prostate Cancer

HIFU (Ablatherm) Complications

HIFU (Sonablate) Complications

Surgery Complications

Surgery Short Term Complications

Radiotherapy Complications

HIFU Long Term Complications

Surgery Long Term Complications

Radiotherapy Long Term Complications

Comparison between Ablatherm and Sonablate Complications

1. Ganzer R et al BJU Int. 2013 Aug; 112(3):322-9

2. Crouzet S et al Eur Urol. 2014 May;65(5):907-14

3. Uchida T et al J Urol. 2015 Jan; 193(1):103-10

4. Dickinson L et al Eur Urol 2016 http://dx.doi.org/10.1016/j.eururo.2016.02.054

5. FDA Presentation Ablatherm 2014

6. Ahmed HU et al Br J Cancer. 2009 Jul 7;101(1):19-26

7. Pascal R et al Presented at the 2016 AUA San Diego, CA

8. Ahmed HU et al Eur Urol. 2015 Dec;68(6):927-36

9. Ahmed HU et al Lancet Oncol. 2012 Jun;13(6):622-32

10. van Velthoven R et al Prostate Cancer Prostatic Dis. 2016 Mar;19(1):79-83

11. Feijoo ER et al Eur Urol. 2016 Feb; 69(2):214-20

12. Guillaumier et al Presented at the 2016 AUA San Diego, CA

13. Crouzet et al Radiother Oncol. 2012 Nov;105(2):198-202

14. Ahmed HU et al Cancer. 2012 Jun 15;118(12):3071-8

15. Uchida T et al BJU Int. 2011 Feb; 107(3):378-82

16. FDA Presentation Sonacare 2014